Human epidermal receptor (HER) family receptors are commonly overexpressed in various human tumors, and their overexpression is thought to play a critical role in tumor progression. The aim of this meta-analysis was to evaluate the prognostic significance of HER family members in epithelial ovarian cancer (EOC).
Methods
Relevant studies published between January 1, 1980, and April 24, 2013, that evaluated the associations of HER family members with overall survival (OS), progression-free survival (PFS), response to platinum-based chemotherapy, lymph node metastasis, or ascites in EOC were identified via searches of PubMed and EMBASE.
Results
We identified 37 eligible articles that met the inclusion criteria. The results of the meta-analysis revealed that significantly poorer OS of patients with EOC was predicted by high Her-2 expression levels (hazard ratio [HR] 1.69, 95% confidence interval [CI] 1.31-2.19). Furthermore, high Her-2 expression was significantly associated with poor PFS (HR 1.88, 95% CI 1.46-2.41) and an increased risk of ascites (risk ratio 1.21, 95% CI 1.02-1.42).
Conclusions
High levels of expression of Her-2 are significantly related to poor survival and an increased risk of ascites in patients with EOC. Future prospective cohorts with larger samples are needed to verify the prognostic value of Her-2 expression in EOC.
Get full access to this article
View all access options for this article.
References
1.
SiegelRNaishadhamDJemalACancer statistics, 2013. CA Cancer J Clin2013;63 (1):11–30
2.
AgarwalRKayeSBOvarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer2003;3 (7):502–516
3.
MarmorMDSkariaKBYardenYSignal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys2004;58 (3):903–913
4.
ZhangHBerezovAWangQErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest2007;117 (8):2051–2058
5.
CitriASkariaKBYardenYThe deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res2003;284 (1):54–65
HolbroTCivenniGHynesNEThe ErbB receptors and their role in cancer progression. Exp Cell Res2003;284 (1):99–110
8.
MemonAASorensenSBNexoEThe epidermal growth factor family has a dual role in deciding the fate of cancer cells. Scand J Clin Lab Invest2006;66 (7):623–630
9.
SalomonDSBrandtRCiardielloFNormannoNEpidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol1995;19 (3):183–232
10.
MedenHMarxDRathWOverexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol1994;13 (1):45–53
11.
RaspolliniMRCastiglioneFGarbiniFCorrelation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol2005;13 (2):135–142
12.
SkirnisdóttirISorbeBSeidalTThe growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer2001;11 (2):119–129
13.
TaylorCRStandardization in immunohistochemistry: the role of antigen retrieval in molecular morphology. Biotech Histochem2006;81 (1):3–12
14.
StroupDFBerlinJAMortonSCMeta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA2000;283 (15):2008–2012
15.
ParmarMKTorriVStewartLExtracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med1998;17 (24):2815–2834
16.
HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysis. Stat Med2002;21 (11):1539–1558
17.
DerSimonianRLairdNMeta-analysis in clinical trials. Control Clin Trials1986;7 (3):177–188
18.
MantelNHaenszelWStatistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst1959;22 (4):719–748
19.
EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical test. BMJ1997;315 (7109):629–634
20.
PfistererJDu BoisABentzEKPrognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. Int J Gynecol Cancer2009;19 (1):109–115
21.
QinQSunYFeiMExpression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Neoplasma2012;59 (3):310–315
22.
ShenKLangJGuoL[Overexpression of C-erbB3 in transitional cell carcinoma of the ovary]. Zhonghua Fu Chan Ke Za Zhi1995;30 (11):658–661
23.
TanakaYTeraiYTanabeAPrognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther2011;11 (1):50–57
24.
van der ZeeAGHollemaHSuurmeijerAJValue of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol1995;13 (1):70–78
25.
ZhangJChenAPWangBZhaoSPLiuLZDaiSZ[Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.]Ai Zheng2008;27 (12):1331–1336
26.
GoffBARiesJAElsLPColtreraMDGownAMImmunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol1998;70 (3):378–385
27.
LassusHSihtoHLeminenAGene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med2006;84 (8):671–681
28.
PaateroILassusHJunttilaTTKaskinenMBützowREleniusKCYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol2013;129 (1):179–187
29.
RaspolliniMRAmunniGVillanucciAHER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol2006;14 (2):181–186
30.
LengJLangJShenKGuoLOverexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J1997;12 (2):67–70
31.
Camilleri-BroëtSHardy-BessardACLe TourneauAet al;GINECO group. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol2004;15 (1):104–112
32.
ElieCGeayJFMorcosMet al;GINECO Group. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer2004;91 (3):470–475
33.
FelipEDel CampoJMRubioDVidalMTColomerRBermejoBOverexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer1995;75 (8):2147–2152
34.
HøgdallEVChristensenLKjaerSKDistribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer2003;98 (1):66–73
35.
NielsenJSJakobsenEHølundBBertelsenKJakobsenAPrognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer2004;14 (6):1086–1096
36.
NoskeASchwabeMWeichertWAn intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer2011;11 (1):294
37.
PilsDPinterAReibenweinJIn ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer2007;96 (3):485–491
38.
PsyrriAKassarMYuZEffect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res2005;1124 Pt 1:8637–8643
39.
SteffensenKDWaldstrømMJeppesenUJakobsenEBrandslundIJakobsenAThe prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer2007;17 (4):798–807
40.
TannerBHasencleverDSternKErbB-3 predicts survival in ovarian cancer. J Clin Oncol2006;24 (26):4317–4323
41.
TomićSIlić ForkoJBabićDSundovDKuretSAndelinovićSc-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Croat Med J2003;44 (4):429–434
42.
TuefferdMCouturierJPenault-LlorcaFHER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE2007;2 (11):e1138
43.
VerriEGuglielminiPPuntoniMHER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology2005;682-3:154–161
44.
SkírnisdóttirISeidalTSorbeBA new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer2004;14 (2):259–270
45.
BaekelandtMKristensenGBTropéCGNeslandJMHolmREpidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res1999;195C:4469–4474
46.
FerrandinaGRanellettiFOLauriolaLCyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol2002;85 (2):305–310
47.
HirteHOzaASwenertonKA phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol2010;118 (3):308–312
48.
KupryjańczykJMadryRPlisiecka-HałasaJTP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer2004;91 (11):1916–1923
49.
ProtopapasADiakomanolisEBamiasAThe prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur J Gynaecol Oncol2004;25 (2):225–229
50.
SasakiNKudohKKitaTTsudaHFuruyaKKikuchiYEffect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma. J Obstet Gynaecol Res2007;33 (1):17–23
51.
ScambiaGBenedetti PaniciPFerrandinaGExpression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer. Int J Gynecol Cancer1993;3 (5):271–278
52.
LiLZhongYPZhangWZhangJQYaoZQ[Relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma.]Ai Zheng2004;23 (5):568–572
53.
SueblinvongTManchanaTKhemapechNTriratanachatSTermrungruanglertWTresukosolDLack of prognostic significance of HER-2/neu in early epithelial ovarian cancer. Asian Pac J Cancer Prev2007;8 (4):502–506
54.
CarterTHKungHJTissue-specific transformation by oncogenic mutants of epidermal growth factor receptor. Crit Rev Oncol1994;5 (4):389–428
55.
de GraeffPCrijnsAPde JongSModest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer2009;101 (1):149–159
56.
MénardSTagliabueECampiglioMPupaSMRole of HER2 gene overexpression in breast carcinoma. J Cell Physiol2000;182 (2):150–162
